肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：VISTA/PD-1H可作为非小细胞肺癌免疫治疗靶点

2018-04-24 MedSci MedSci原创

非小细胞肺癌VISTA/PD-1H免疫治疗
关注

VISTA/PD-1H参与免疫调节，临床试验正在评估VISTA阻滞的抗肿瘤效果。但是，人恶性肿瘤VISTA表达的生物学影响尚缺乏进一步研究。CLIN CANCER RES近期发表了一篇文章，研究VISTA/PD-1H在非小细胞肺癌中的临床意义。

VISTA/PD-1H参与免疫调节，临床试验正在评估VISTA阻滞的抗肿瘤效果。但是，人恶性肿瘤VISTA表达的生物学影响尚缺乏进一步研究。CLIN CANCER RES近期发表了一篇文章，研究VISTA/PD-1H在非小细胞肺癌中的临床意义。

作者分析了来自3个独立队列的758例Ⅰ-Ⅳ期非小细胞肺癌患者的VISTA，PD-1和PD-L1蛋白情况。选择性的评估目标蛋白在角蛋白阳性肿瘤上皮细胞，CD3+T细胞，CD4+T辅助细胞，CD8+细胞毒T细胞，CD20+B淋巴细胞和CD68+肿瘤相关巨噬细胞表达情况。将目标蛋白，临床病理/分子变量和预后相联系。对TCGA数据库的肺癌样本进行基因组分析。研究结果发现，99%的非小细胞肺癌肺癌患者中检测到VISTA蛋白。21%的患者肿瘤细胞表达，98%的患者基质细胞表达。VISTA水平与PD-1，PD-L1，CD8+T细胞和CD68+巨噬细胞正相关。T淋巴细胞中VISTA表达高于巨噬细胞，细胞毒T细胞表达高于T辅助细胞。VISTA表达增加与EGFR突变缺失及肺腺癌突变负荷低有关。

文章最后认为，VISTA频繁表达于非小细胞肺癌中，且与肿瘤浸润淋巴细胞增加，PD-1轴标志，特异性基因改变和结局改善有关。这些研究结果支持VISTA在非小细胞肺癌中发挥的免疫调节作用，且提示其可以作为治疗靶点。

原始出处：
Franz Villarroel-Espindola,Xiaoqing Yu,et al.Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer.CLIN CANCER RES.April 2018 doi:10.1158/1078-0432.CCR-17-2542

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2059701, encodeId=b0622059e01ee, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Feb 06 06:39:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669225, encodeId=c7961669225b5, content=<a href='/topic/show?id=561b1846324' target=_blank style='color:#2F92EE;'>#VISTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18463, encryptionId=561b1846324, topicName=VISTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d46d26532205, createdName=muzishouyi, createdTime=Mon Jul 09 06:39:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895366, encodeId=df8018953660f, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Mon Oct 29 21:39:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315977, encodeId=e6073159e788, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Thu May 17 11:31:05 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308915, encodeId=2d4030891558, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Apr 24 20:25:23 CST 2018, time=2018-04-24, status=1, ipAttribution=)]
    2019-02-06 lingaifan

    #非小细胞#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2059701, encodeId=b0622059e01ee, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Feb 06 06:39:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669225, encodeId=c7961669225b5, content=<a href='/topic/show?id=561b1846324' target=_blank style='color:#2F92EE;'>#VISTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18463, encryptionId=561b1846324, topicName=VISTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d46d26532205, createdName=muzishouyi, createdTime=Mon Jul 09 06:39:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895366, encodeId=df8018953660f, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Mon Oct 29 21:39:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315977, encodeId=e6073159e788, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Thu May 17 11:31:05 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308915, encodeId=2d4030891558, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Apr 24 20:25:23 CST 2018, time=2018-04-24, status=1, ipAttribution=)]
    2018-07-09 muzishouyi

    #VISTA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2059701, encodeId=b0622059e01ee, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Feb 06 06:39:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669225, encodeId=c7961669225b5, content=<a href='/topic/show?id=561b1846324' target=_blank style='color:#2F92EE;'>#VISTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18463, encryptionId=561b1846324, topicName=VISTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d46d26532205, createdName=muzishouyi, createdTime=Mon Jul 09 06:39:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895366, encodeId=df8018953660f, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Mon Oct 29 21:39:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315977, encodeId=e6073159e788, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Thu May 17 11:31:05 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308915, encodeId=2d4030891558, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Apr 24 20:25:23 CST 2018, time=2018-04-24, status=1, ipAttribution=)]
    2018-10-29 drj2003

    #治疗靶点#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2059701, encodeId=b0622059e01ee, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Feb 06 06:39:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669225, encodeId=c7961669225b5, content=<a href='/topic/show?id=561b1846324' target=_blank style='color:#2F92EE;'>#VISTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18463, encryptionId=561b1846324, topicName=VISTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d46d26532205, createdName=muzishouyi, createdTime=Mon Jul 09 06:39:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895366, encodeId=df8018953660f, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Mon Oct 29 21:39:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315977, encodeId=e6073159e788, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Thu May 17 11:31:05 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308915, encodeId=2d4030891558, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Apr 24 20:25:23 CST 2018, time=2018-04-24, status=1, ipAttribution=)]
    2018-05-17 hanmeijinxiu

    学习了.谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2059701, encodeId=b0622059e01ee, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Feb 06 06:39:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669225, encodeId=c7961669225b5, content=<a href='/topic/show?id=561b1846324' target=_blank style='color:#2F92EE;'>#VISTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18463, encryptionId=561b1846324, topicName=VISTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d46d26532205, createdName=muzishouyi, createdTime=Mon Jul 09 06:39:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895366, encodeId=df8018953660f, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Mon Oct 29 21:39:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315977, encodeId=e6073159e788, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Thu May 17 11:31:05 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308915, encodeId=2d4030891558, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Apr 24 20:25:23 CST 2018, time=2018-04-24, status=1, ipAttribution=)]
    2018-04-24 虈亣靌

    学习了.获益匪浅.感谢分享

    0

相关资讯

NEJM：纳武单抗联合易普利姆玛可改善高突变负担肺癌患者生存

研究认为，纳武单抗联合易普利姆玛的肿瘤免疫治疗可显著延长高突变负担非小细胞肺癌患者的无进展生存期，该研究结果支持纳武单抗联合易普利姆玛用于晚期非小细胞肺癌肺癌的一线治疗

2018 ASTRO循证指南：非小细胞肺癌姑息胸部放疗（更新版）

2018年4月，美国放射治疗及肿瘤学会(ASTRO)更新发布了非小细胞肺癌姑息胸部放疗指南，该指南是对2011版指南的更新，指南针对姑息胸部外放射治疗新增3个关键问题：剂量和分级，支气管的效用近距离放射疗法，放化疗的并发症。

Radiology：计算机辅助CT测量亚实性结节实性成分评估预后的价值

本研究旨在验证亚实性非小细胞肺癌患者术后情况与多螺旋CT图像3D容积软件中所测实性成分大小的关系，并将结果发表在Radiology上。

NEJM：纳武单抗用于可切除非小细胞肺癌的辅助治疗

研究认为，对于可切除的早期非小细胞肺癌患者，接受纳武单抗辅助治疗的副作用小，不干扰手术，可使约50%的肿瘤组织出现主要病理反应

Sci Rep：超声引导下支气管内支气管刷检在周围型非鳞状非小细胞肺癌中的价值

R-EBUS引导下支气管刷检为周围型肺癌患者的诊断和EGFR基因分型提供了额外的取样方法。

2018 ESTRO指南：局部进展期非小细胞肺癌治疗中靶区定义

放射治疗在局部进展期非小细胞肺癌的根治中起了重要作用，欧洲放射肿瘤学学会(ESTRO)ACROP委员会针对放疗靶区勾画提出了指导建议，内容涉及局部进展期非小细胞肺癌的诊断和影像学检查，计划CT扫描，放疗接话附加影像检查，放疗剂量等。